Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis

Table 2 Clinicopathological and immunohistochemical characteristics of primary breast carcinomas

Variable	Categorization	IHC		Realtime PCR
		n¹	%	n¹	%
*Clinicopathological factor:*
Age at diagnosis
Median, range (years)		57.5 (25–82)		57.5 (28–85)
	≤ 50 years	54	29.2	10	27.8
	> 50 years	128	69.2	26	72.2
	unknown	3	1.6	0	0
Tumor stage²
	pT1	46	24.9	15	41.7
	pT2	92	49.7	16	44.4
	pT3	13	7.0	0	0
	pT4	30	16.2	4	11.1
	pTx³	4	2.2	1	2.8
Lymph node status²
	pN0	71	38.4	19	52.8
	pN1–3	104	56.2	15	41.7
	pNx³	10	5.4	2	5.6
Grading
	G1/G2	100	54.1	19	52.8
	G3	80	43.2	15	41.7
	Gx³	5	2.7	2	5.6
Histological type
	ductal	145	78.4	34	94.4
	lobular	13	7.0	1	2.8
	other	19	10.3	1	2.8
	unknown	8	4.3	0	0
*Immunohistochemistry (IHC):*
Estrogen receptor status
	negative (IRS⁴ 0–2)	49	26.5	11	30.6
	positive (IRS 3–12)	97	52.4	21	58.3
	unknown	39	21.1	4	11.1
Progesterone receptor status
	negative (IRS⁴ 0–2)	107	57.8	12	33.3
	positive (IRS 3–12)	49	26.5	20	55.6
	unknown	29	15.7	4	11.1
HER2 expression status
	negative (0–1+)	120	64.9	6	16.7
	positive (2+-3+)	38	20.5	5	13.9
	unknown	27	14.6	25	69.4

Characteristics of primary breast carcinomas used for ITIH2 immunohistochemistry (n = 185) and real-time PCR (n = 36) analysis.
¹Only female patients with primary invasive breast cancer were included. ²According to UICC: TNM Classification of Malignant Tumours (2002) [65]. ³x = status unknown. ⁴IRS = Immunoreactivity score according to Remmele and Stegner (1987) [47].